NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
NeoPharm CO. LTD (KQ: 092730)
092730 Technical Analysis
4
As on 14th Aug 2025 092730 STOCK Price closed @ 18750.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 22107.12 & Strong Sell for SHORT-TERM with Stoploss of 25061.82 we also expect STOCK to react on Following IMPORTANT LEVELS. |
092730STOCK Price
Open | 17400.00 | Change | Price | % |
High | 18920.00 | 1 Day | 1340.00 | 7.70 |
Low | 17250.00 | 1 Week | 960.00 | 5.40 |
Close | 18750.00 | 1 Month | 4380.00 | 30.48 |
Volume | 323966 | 1 Year | -8300.00 | -30.68 |
52 Week High 33200.00 | 52 Week Low 10810.00 |
KQ Korea Most Active Stocks
207760 | 1782.00 | 11.17% |
032980 | 302.00 | 16.15% |
009270 | 1953.00 | 5.28% |
009270 | 1953.00 | 5.28% |
007980 | 1928.00 | 15.45% |
007980 | 1928.00 | 15.45% |
208640 | 622.00 | -14.21% |
072770 | 617.00 | 12.18% |
043220 | 171.00 | -29.63% |
321260 | 2560.00 | 0.59% |
KQ Korea Top Gainers Stocks
KQ Korea Top Losers Stocks
092730 Daily Charts |
092730 Intraday Charts |
Whats New @ Bazaartrend |
092730 Free Analysis |
|
092730 Important Levels Intraday
RESISTANCE | 21968.09 |
RESISTANCE | 20936.03 |
RESISTANCE | 20298.09 |
RESISTANCE | 19660.15 |
SUPPORT | 17839.85 |
SUPPORT | 17201.91 |
SUPPORT | 16563.97 |
SUPPORT | 15531.91 |
092730 Forecast August 2025
4th UP Forecast | 25301.8 |
3rd UP Forecast | 23200.6 |
2nd UP Forecast | 21901.8 |
1st UP Forecast | 20603 |
1st DOWN Forecast | 16897 |
2nd DOWN Forecast | 15598.2 |
3rd DOWN Forecast | 14299.4 |
4th DOWN Forecast | 12198.2 |
092730 Weekly Forecast
4th UP Forecast | 23374.80 |
3rd UP Forecast | 21891.60 |
2nd UP Forecast | 20974.80 |
1st UP Forecast | 20058.00 |
1st DOWN Forecast | 17442.00 |
2nd DOWN Forecast | 16525.20 |
3rd DOWN Forecast | 15608.40 |
4th DOWN Forecast | 14125.20 |
092730 Forecast2025
4th UP Forecast | 64227.2 |
3rd UP Forecast | 49642.4 |
2nd UP Forecast | 40627.2 |
1st UP Forecast | 31612 |
1st DOWN Forecast | 5888 |
2nd DOWN Forecast | -3127.2 |
3rd DOWN Forecast | -12142.4 |
4th DOWN Forecast | -26727.2 |
NeoPharm CO. LTD ( KQ Korea Symbol : 092730 )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
092730 Other Details
Segment | EQ | |
Market Capital | 218890387456.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
092730 Address
![]() |
092730 Latest News
092730 Business Profile
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, South Korea. Address: 309-8, Techno 2-ro, Daejeon, South Korea
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service